chloroquine has been researched along with Respiratory Syndrome, Acute, Severe in 10 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro." | 7.72 | In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. ( Keyaerts, E; Maes, P; Neyts, J; Van Ranst, M; Vijgen, L, 2004) |
| "Chloroquine has been sporadically used in treating SARS-CoV-2 infection." | 5.56 | In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ( Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020) |
| "We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro." | 3.72 | In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. ( Keyaerts, E; Maes, P; Neyts, J; Van Ranst, M; Vijgen, L, 2004) |
| "Sarcoidosis is an autoinflammatory disease characterized by the diffusion of granulomas in the lungs and other organs." | 2.66 | Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis. ( Calender, A; Israel-Biet, D; Pacheco, Y; Valeyre, D, 2020) |
| "Chloroquine is a 9-aminoquinoline known since 1934." | 2.42 | Effects of chloroquine on viral infections: an old drug against today's diseases? ( Boelaert, JR; Cassone, A; Cauda, R; Majori, G; Savarino, A, 2003) |
| "Chloroquine has been sporadically used in treating SARS-CoV-2 infection." | 1.56 | In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ( Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maxmen, A | 1 |
| Yao, X | 1 |
| Ye, F | 1 |
| Zhang, M | 1 |
| Cui, C | 1 |
| Huang, B | 1 |
| Niu, P | 1 |
| Liu, X | 1 |
| Zhao, L | 1 |
| Dong, E | 1 |
| Song, C | 1 |
| Zhan, S | 1 |
| Lu, R | 1 |
| Li, H | 1 |
| Tan, W | 1 |
| Liu, D | 1 |
| Wang, Y | 1 |
| Zhu, LQ | 1 |
| Kang, Y | 1 |
| Chen, T | 1 |
| Mui, D | 1 |
| Ferrari, V | 1 |
| Jagasia, D | 1 |
| Scherrer-Crosbie, M | 1 |
| Chen, Y | 1 |
| Han, Y | 1 |
| Calender, A | 1 |
| Israel-Biet, D | 1 |
| Valeyre, D | 1 |
| Pacheco, Y | 1 |
| Ogah, OS | 1 |
| Umuerri, EM | 1 |
| Adebiyi, A | 1 |
| Orimolade, OA | 1 |
| Sani, MU | 1 |
| Ojji, DB | 1 |
| Mbakwem, AC | 1 |
| Stewart, S | 1 |
| Sliwa, K | 1 |
| Savarino, A | 2 |
| Boelaert, JR | 1 |
| Cassone, A | 2 |
| Majori, G | 1 |
| Cauda, R | 2 |
| Keyaerts, E | 1 |
| Vijgen, L | 1 |
| Maes, P | 1 |
| Neyts, J | 1 |
| Van Ranst, M | 1 |
| Vincent, MJ | 1 |
| Bergeron, E | 1 |
| Benjannet, S | 1 |
| Erickson, BR | 1 |
| Rollin, PE | 1 |
| Ksiazek, TG | 1 |
| Seidah, NG | 1 |
| Nichol, ST | 1 |
| Di Trani, L | 1 |
| Donatelli, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh[NCT04434144] | 116 participants (Actual) | Observational [Patient Registry] | 2020-05-02 | Completed | |||
| Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial[NCT04339816] | Phase 3 | 3 participants (Actual) | Interventional | 2020-05-13 | Terminated (stopped due to Steering Committee decision in accordance with stopping rule 1: Emergence of new data) | ||
| Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441] | Phase 2 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Not started) | ||
| Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial[NCT04359095] | Phase 2/Phase 3 | 650 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study[NCT04341441] | Phase 3 | 624 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.) | ||
| Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467] | Phase 2 | 3,217 participants (Actual) | Interventional | 2020-03-28 | Completed | ||
| Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine in Colombia[NCT04654416] | 301 participants (Actual) | Observational | 2020-03-20 | Completed | |||
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment[NCT04334967] | Phase 4 | 13 participants (Actual) | Interventional | 2020-03-30 | Suspended (stopped due to suspected unfavorable risk/benefit assessment) | ||
| A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2020-04-17 | Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias) | ||
| Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial[NCT04491994] | Phase 3 | 540 participants (Actual) | Interventional | 2020-04-10 | Completed | ||
| Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study[NCT04380870] | 500 participants (Anticipated) | Observational | 2020-05-11 | Recruiting | |||
| Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial[NCT04345289] | Phase 3 | 147 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to DSMB advise due to high probability of futility) | ||
| A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting[NCT04370782] | Phase 4 | 18 participants (Actual) | Interventional | 2020-04-28 | Completed | ||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| Observational Study of COVID-19 Treatment Efficacy[NCT04369989] | 250 participants (Actual) | Observational | 2020-04-14 | Terminated (stopped due to Review of data revealed poor correlation with hypothesis and data quality challenges.) | |||
| A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation[NCT00819390] | Phase 2 | 70 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization[NCT04365582] | Phase 3 | 0 participants (Actual) | Interventional | 2020-05-07 | Withdrawn (stopped due to The PI decided.) | ||
| Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts[NCT04652648] | Phase 4 | 54 participants (Actual) | Interventional | 2020-05-27 | Completed | ||
| A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493] | Phase 2 | 10 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19[NCT04349592] | 456 participants (Actual) | Interventional | 2020-04-14 | Completed | |||
| Impact of Colchicine in Hospitalized Colombian Patients With COVID-19[NCT04539873] | Phase 3 | 128 participants (Actual) | Interventional | 2021-04-30 | Terminated (stopped due to non-inclusion of patients in the study effectively) | ||
| Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)[NCT04400019] | Phase 2/Phase 3 | 1,930 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compare the rates of SARS-CoV 2 infections (number of events of symptomatic patients with a positive COVID-19 test) in the non-randomized comparator arm to the randomized hydroxychloroquine and placebo arms to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples. This analysis includes all randomized and non-randomized groups in the study. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Measurement of the seroprevalence of SARS-CoV 2 IgM and/or IgG positive samples in all arms of the study, randomized and non-randomized (Study Drug - Daily Dose, Study Drug - Weekly Dose, Placebo, and Non-Randomized Active Comparator). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
| Non-Randomized Active Comparator | 0 |
Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples in the randomized arms of the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
Compare the rates of SARS-CoV 2 symptomatic infections (number of events with both symptoms and positive test for COVID-19) between the randomized hydroxychloroquine treatment arms and the placebo control arm to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease. This analysis only includes only the randomized arms in the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
Examination of the correlation between HCQ drug levels and development of COVID-19 clinical symptoms and/or positive COVID-19 test results via weekly subject questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Correlation coefficient (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples. (NCT04341441)
Timeframe: 8 weeks
| Intervention | Inflammatory markers (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Examination of other clinical factors contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Clinical factors (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 0 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Number of adverse events. (Number) | |
|---|---|---|
| Adverse events (only Level 1 and 2) observed in the study. | Serious adverse events (Level 3 or 4). | |
| Non-Randomized Active Comparator | 2 | 0 |
| Placebo | 188 | 0 |
| Study Drug - Daily Dose | 206 | 0 |
| Study Drug - Weekly Dose | 193 | 0 |
Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial
| Intervention | participants (Number) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 1 |
Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Control | 2 |
After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status (NCT04491994)
Timeframe: 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care (SOC) | 5 |
| Intervention Group | 11 |
The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -2.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | -0.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -3.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -1.2 |
The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Pre-entry, entry, Weeks 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 10.8 |
| C: Chloroquine Then Placebo for On-ART Participants | -2.4 |
For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: For Arms A and C: Pre-entry, entry, weeks 10 and 12. For Arms B and D: Weeks 10, 12, 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -2.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -3.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -2.9 |
The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+ (NCT00819390)
Timeframe: At Weeks 10, 12, 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 5.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -0.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -2.9 |
Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12
| Intervention | cells/mm^3 (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -27 |
| B: Placebo Then Chloroquine for Off-ART Participants | -11 |
| C: Chloroquine Then Placebo for On-ART Participants | -6 |
| D: Placebo Then Chloroquine for On-ART Participants | 7 |
Results reported are for entry fasting LPS. (NCT00819390)
Timeframe: At entry
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 13.68 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.64 |
| C: Chloroquine Then Placebo for On-ART Participants | 8.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 7.00 |
Results reported are the week 12 fasting LPS. (NCT00819390)
Timeframe: At week 12
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 14.37 |
| B: Placebo Then Chloroquine for Off-ART Participants | 13.06 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 7.00 |
Results reported are the week 24 fasting LPS. (NCT00819390)
Timeframe: At week 24
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 20.54 |
| B: Placebo Then Chloroquine for Off-ART Participants | 2.83 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 8.00 |
Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants. (NCT00819390)
Timeframe: At Entry
| Intervention | log10 copies/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 4.48 |
| B: Placebo Then Chloroquine for Off-ART Participants | 4.42 |
Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment. (NCT00819390)
Timeframe: From start of study treatment to study completion at week 28
| Intervention | participants (Number) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1 |
| C: Chloroquine Then Placebo for On-ART Participants | 1 |
| D: Placebo Then Chloroquine for On-ART Participants | 0 |
Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 8.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 9.8 |
| C: Chloroquine Then Placebo for On-ART Participants | 8.7 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.9 |
Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 12
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 6.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 10.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.7 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.0 |
Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 24
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 11.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 12.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.3 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.2 |
Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 71.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 77.0 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.8 |
| D: Placebo Then Chloroquine for On-ART Participants | 49.9 |
Results reported are the week 12 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 12
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 71.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 79.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.9 |
| D: Placebo Then Chloroquine for On-ART Participants | 51.9 |
Results reported are the week 24 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 24
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 78.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 79.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.6 |
| D: Placebo Then Chloroquine for On-ART Participants | 48.7 |
Baseline sCD14 was computed as the mean of pre-entry and entry sCD14. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.43 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.97 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.80 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.58 |
Results reported are the week 12 sCD14. (NCT00819390)
Timeframe: At week 12
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.88 |
| C: Chloroquine Then Placebo for On-ART Participants | 2.04 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.63 |
Results reported are the week 24 sCD14. (NCT00819390)
Timeframe: At week 24
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 2.19 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.77 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.72 |
Results reported are for HIV-1 RNA at study entry for on-ART participants. (NCT00819390)
Timeframe: At Entry
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 16 | 2 |
| D: Placebo Then Chloroquine for On-ART Participants | 17 | 2 |
Results reported are for HIV-1 RNA at week 12 for on-ART participants. (NCT00819390)
Timeframe: At week 12
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 16 | 1 |
| D: Placebo Then Chloroquine for On-ART Participants | 18 | 1 |
Results reported are for HIV-1 RNA at week 24 for on-ART participants. (NCT00819390)
Timeframe: At week 24
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 14 | 2 |
| D: Placebo Then Chloroquine for On-ART Participants | 18 | 1 |
Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants. (NCT00819390)
Timeframe: At weeks 12 and 24
| Intervention | log10 copies/mL (Median) | |
|---|---|---|
| Week 12 | Week 24 | |
| A: Chloroquine Then Placebo for Off-ART Participants | 4.68 | 4.69 |
| B: Placebo Then Chloroquine for Off-ART Participants | 4.28 | 4.61 |
Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.65 | 1228.66 | 286390 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.62 | 1377.81 | 328460 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.01 | 1316.63 | 107890 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.51 | 1250.85 | 103530 |
Results reported are the week 12 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 12
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.68 | 1209.50 | 251320 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.28 | 1347.06 | 319770 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.15 | 1441.35 | 126540 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.30 | 1304.77 | 117890 |
Results reported are the week 24 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 24
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.34 | 1327.21 | 264240 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.18 | 1420.30 | 294780 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.02 | 1230.21 | 100860 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.27 | 1176.20 | 124920 |
Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.03 | 45.48 | 9.12 | 2.52 | 1.04 | 38.60 | 96.29 | 9.82 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.03 | 36.15 | 9.35 | 6.13 | 0.83 | 39.94 | 97.52 | 16.37 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.13 | 19.91 | 10.96 | 4.48 | 1.31 | 48.17 | 96.11 | 4.58 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.07 | 23.65 | 12.66 | 6.49 | 1.17 | 26.08 | 95.38 | 8.28 |
Results reported are the week 12 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 12
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.00 | 51.90 | 7.66 | 3.74 | 0.84 | 43.51 | 97.90 | 15.03 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.05 | 40.49 | 8.48 | 8.43 | 1.03 | 36.47 | 97.18 | 16.32 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.10 | 14.70 | 13.93 | 7.24 | 1.47 | 47.83 | 95.40 | 7.10 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.14 | 18.20 | 13.64 | 5.16 | 1.01 | 26.75 | 95.15 | 6.09 |
Results reported are the week 24 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 24
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.05 | 44.50 | 10.13 | 4.34 | 0.94 | 41.21 | 97.70 | 9.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.00 | 38.96 | 7.89 | 7.45 | 1.12 | 33.19 | 97.05 | 14.84 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.08 | 14.80 | 11.79 | 5.63 | 0.76 | 36.65 | 96.69 | 4.13 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.16 | 17.65 | 12.88 | 6.52 | 1.39 | 24.14 | 92.41 | 7.49 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
5 reviews available for chloroquine and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; China; Chloroquine; Coronavirus | 2020 |
Cardiovascular manifestations and treatment considerations in COVID-19.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh | 2020 |
Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Autophagy; Azithromycin; Betacoronavirus; Chloroquine; Cor | 2020 |
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chlor | 2021 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
Effects of chloroquine on viral infections: an old drug against today's diseases?
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Chloroquine; Humans; Immune System; Severe Acute | 2003 |
5 other studies available for chloroquine and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
More than 80 clinical trials launch to test coronavirus treatments.
Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Betacoronavirus; China; Chloroquine; Cli | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Chloroquine; Coronaviru | 2020 |
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.
Topics: Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; Dose-Response Relations | 2004 |
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.
Topics: Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; Dose-Response Relations | 2004 |
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.
Topics: Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; Dose-Response Relations | 2004 |
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.
Topics: Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; Dose-Response Relations | 2004 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; | 2005 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Dru | 2006 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Dru | 2006 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Dru | 2006 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Dru | 2006 |